These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

105 related items for PubMed ID: 17724740

  • 1. Adverse effects during the treatment with pegylated interferon and ribavirin in children with chronic hepatitis C.
    Kowala-Piaskowska A, Mozer-Lisewska I, Figlerowicz M, Słuzewski W.
    Pharmacoepidemiol Drug Saf; 2007 Oct; 16(10):1095-103. PubMed ID: 17724740
    [Abstract] [Full Text] [Related]

  • 2. [Thyroid dysfunctions in children with chronic hepatitis C during interferon alpha-2b therapy].
    Kupś-Rzepecka J, Woźniakowska-Gesicka T, Gołabek V.
    Przegl Lek; 2011 Oct; 68(6):311-5. PubMed ID: 22039668
    [Abstract] [Full Text] [Related]

  • 3. Transient Hypothyroidism and Autoimmune Thyroiditis in Children With Chronic Hepatitis C Treated With Pegylated-interferon-α-2b and Ribavirin.
    Serranti D, Indolfi G, Nebbia G, Cananzi M, D'Antiga L, Ricci S, Stagi S, Azzari C, Resti M, Italian Study Group for Treatment of Chronic Hepatitis C in Children.
    Pediatr Infect Dis J; 2018 Apr; 37(4):287-291. PubMed ID: 28953189
    [Abstract] [Full Text] [Related]

  • 4. Comparison of low-dose pegylated interferon versus standard high-dose pegylated interferon in combination with ribavirin in patients with chronic hepatitis C with genotype 3: an Indian experience.
    Sood A, Midha V, Hissar S, Kumar M, Suneetha PV, Bansal M, Sood N, Sakhuja P, Sarin SK.
    J Gastroenterol Hepatol; 2008 Feb; 23(2):203-7. PubMed ID: 17645472
    [Abstract] [Full Text] [Related]

  • 5. Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C.
    Wirth S, Pieper-Boustani H, Lang T, Ballauff A, Kullmer U, Gerner P, Wintermeyer P, Jenke A.
    Hepatology; 2005 May; 41(5):1013-8. PubMed ID: 15793840
    [Abstract] [Full Text] [Related]

  • 6. [Early virologic response in retherapy with pegylated interferon alpha-2B plus ribavirin in children with chronic hepatitis C].
    Pawłowska M, Palewicz E, Halota W.
    Przegl Epidemiol; 2006 May; 60(1):71-7. PubMed ID: 16758742
    [Abstract] [Full Text] [Related]

  • 7. [Effects of treatment with pegylated interferon and ribavirin in children with chronic hepatitis C].
    Kowala-Piaskowska A, Figlerowicz M, Mozer-Lisewska I, Słuzewski W.
    Przegl Epidemiol; 2005 May; 59(2):491-8. PubMed ID: 16190558
    [Abstract] [Full Text] [Related]

  • 8. Adverse skin reactions due to pegylated interferon alpha 2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus.
    Hashimoto Y, Kanto H, Itoh M.
    J Dermatol; 2007 Aug; 34(8):577-82. PubMed ID: 17683392
    [Abstract] [Full Text] [Related]

  • 9. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.
    Bronowicki JP, Ouzan D, Asselah T, Desmorat H, Zarski JP, Foucher J, Bourlière M, Renou C, Tran A, Melin P, Hézode C, Chevalier M, Bouvier-Alias M, Chevaliez S, Montestruc F, Lonjon-Domanec I, Pawlotsky JM.
    Gastroenterology; 2006 Oct; 131(4):1040-8. PubMed ID: 17030174
    [Abstract] [Full Text] [Related]

  • 10. Comparison of two PEG-interferon alpha-2b doses (1.0 or 1.5 microg/kg) combined with ribavirin in interferon-naïve patients with chronic hepatitis C and up to moderate fibrosis.
    Meyer-Wyss B, Rich P, Egger H, Helbling B, Müllhaupt B, Rammert C, Gonvers JJ, Oneta C, Criblez D, Rossi L, Borovicka J, Meyenberger C, Arn M, Renner EL, Swiss Association for the Study of the Liver (SASL).
    J Viral Hepat; 2006 Jul; 13(7):457-65. PubMed ID: 16792539
    [Abstract] [Full Text] [Related]

  • 11. Pegylated interferon-alpha 2b-ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis.
    Derbala M, Amer A, Bener A, Lopez AC, Omar M, El Ghannam M.
    J Viral Hepat; 2005 Jul; 12(4):380-5. PubMed ID: 15985008
    [Abstract] [Full Text] [Related]

  • 12. [The role and possibilities of natural interferon treatment in chronic hepatitis C: experience with natural interferon treatment for patients barred from combined antiviral therapy because of the STOP rule].
    Horváth G, Tolvaj G, Halász T, Stotz G.
    Orv Hetil; 2007 Aug 19; 148(33):1545-50. PubMed ID: 17686672
    [Abstract] [Full Text] [Related]

  • 13. A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group.
    Glue P, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, Salfi M, Jacobs S, Clement RP.
    Hepatology; 2000 Sep 19; 32(3):647-53. PubMed ID: 10960463
    [Abstract] [Full Text] [Related]

  • 14. Treatment of genotype 1b HCV-related chronic hepatitis: efficacy and toxicity of three different interferon alfa-2b/ribavirin combined regimens in naive patients.
    Scotto G, Fazio V, Palumbo E, Cibelli DC, Saracino A, Angarano G.
    New Microbiol; 2005 Jan 19; 28(1):23-9. PubMed ID: 15782623
    [Abstract] [Full Text] [Related]

  • 15. Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.
    Kang HM, Park MJ, Hwang JM, Kim JW, Jeong SH.
    Korean J Hepatol; 2009 Jun 19; 15(2):209-15. PubMed ID: 19581773
    [Abstract] [Full Text] [Related]

  • 16. [Haematologic adverse effects of treatment of chronic viral hepatitis B and C].
    Porubcin S, Schréter I, Kristian P, Pellová A.
    Klin Mikrobiol Infekc Lek; 2008 Apr 19; 14(2):74-8. PubMed ID: 18756437
    [Abstract] [Full Text] [Related]

  • 17. Hemolytic anemia during pegylated IFN-alpha2b plus ribavirin treatment for chronic hepatitis C: ribavirin is not always the culprit.
    Gentile I, Viola C, Reynaud L, Borrelli F, Cerini R, Ciampi R, Piazza M, Borgia G.
    J Interferon Cytokine Res; 2005 May 19; 25(5):283-5. PubMed ID: 15871666
    [Abstract] [Full Text] [Related]

  • 18. Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin.
    Antonini MG, Babudieri S, Maida I, Baiguera C, Zanini B, Fenu L, Dettori G, Manno D, Mura MS, Carosi G, Puoti M.
    Infection; 2008 Jun 19; 36(3):250-5. PubMed ID: 18458815
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of peginterferon-alpha2b and ribavirin combination therapy in children with chronic hepatitis C infection.
    Jara P, Hierro L, de la Vega A, Díaz C, Camarena C, Frauca E, Miños-Bartolo G, Díez-Dorado R, de Guevara CL, Larrauri J, Rueda M.
    Pediatr Infect Dis J; 2008 Feb 19; 27(2):142-8. PubMed ID: 18174875
    [Abstract] [Full Text] [Related]

  • 20. A prospective assessment of an 'a la carte' regimen of PEG-interferon alpha2b and ribavirin combination in patients with chronic hepatitis C using biochemical markers.
    d'Arondel C, Munteanu M, Moussalli J, Thibault V, Naveau S, Simon A, Messous D, Morra R, Blot C, Poynard T.
    J Viral Hepat; 2006 Mar 19; 13(3):182-9. PubMed ID: 16475994
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.